CAPTRUST Financial Advisors’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
VPM
VCM
DTC
CAPTRUST Financial Advisors's AXSM Position: Q1 2026 in Review
CAPTRUST Financial Advisors increased its Axsome Therapeutics (AXSM) stake by 2.9% in Q1 2026, buying an estimated $55.6K and bringing the position to 11,566 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1236.
CAPTRUST Financial Advisors first reported a position in AXSM in Q4 2019 and has held it in 19 quarters since. The position peaked at $2.05M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- CAPTRUST Financial Advisors held 11,566 shares of Axsome Therapeutics worth $1.95M as of Q1 2026.
- CAPTRUST Financial Advisors bought 322 Axsome Therapeutics shares in Q1 2026, an estimated $55.6K.
- Axsome Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1236 holding.
- CAPTRUST Financial Advisors first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 19 quarters since.
- CAPTRUST Financial Advisors's Axsome Therapeutics position peaked at $2.05M in Q4 2025.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.